Connect with us
European Gaming Congress 2024

Artificial Intelligence

At 5.70% CAGR, Global Pharmaceutical Market Size to Hit US$ 2067.36 Million by 2028: Technological Advances are helping the pharmaceutical market grow | Industry Trends, Value, Demand, Analysis & Forecast Report by Facts & Factors

Published

on

NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) — According to Facts and Factors has published a new research report titled “Pharmaceutical Market Size, Share, Growth Analysis Report By API Type (Synthetic API, Biotech API, Monoclonal Antibodies, Cytokines, Vaccines, Blood Factors, Hormones & Growth Factors, Fusion Proteins, and Therapeutic Enzymes), By Drug (Prescription Drugs and OTC Drugs), By Customer Base (Generic Drugs and Branded Drugs), Application (Oncology, Ophthalmology, Cardiovascular Disease, Gastrointestinal Disorders, Diabetes, Endocrinology, Central Nervous System & Neurological Disorders, Nephrology, and Others), and By Region – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028” in its research database.

“According to the latest research study, the demand of global Pharmaceutical Market size & share in terms of revenue was worth of USD 1,482.4 million in 2021 and it is expected to surpass at around USD 2,067.36 million mark by 2028, growing at a compound annual growth rate (CAGR) of approximately 5.70% during the forecast period 2022 to 2028.”

What is Pharmaceutical? How big is the Pharmaceutical Industry?

Market Overview:

The pharmaceuticals market is made up of businesses (organizations, sole proprietorships, and partnerships) that develop drugs used to treat illnesses and sell those drugs as well as associated services. Pharmaceuticals can refer to any kind of medication used to treat illnesses or for medical purposes. Businesses that manufacture pharmaceuticals and biologics are a part of this sector. Pharmaceutical medications and biologics are the two market segments for pharmaceuticals. Drugs are available from pharmaceutical companies for individualized, personalized therapy of many disorders.

Advertisement
Stake.com

Precision medicine, another name for personalized medicine, strives to deliver medical care in accordance with the patient’s unique traits and genetic makeup. Precision therapies are being used more frequently as businesses abandon the one-size-fits-all approach to treating common medical ailments.

Click Here To AccessFree Sample Report of the Global Pharmaceutical Market @ https://www.fnfresearch.com/sample/pharmaceutical-market

(A free sample of this report is available upon request; please contact us for more information.)

Our Free Sample Report Consists of the Following:

  • Introduction, Overview, and in-depth industry analysis are all included in the 2022 updated report.
  • The COVID-19 Pandemic Outbreak Impact Analysis is included in the package
  • About 240+ Pages Research Report (Including Recent Research)
  • Provide detailed chapter-by-chapter guidance on Request
  • Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2022
  • Includes Tables and figures have been updated
  • The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
  • Facts and Factors research methodology

(Please note that the sample of this report has been modified to include the COVID-19 impact study prior to delivery.)

Report Scope

Advertisement
Stake.com
Report Attribute Details
Market Size in 2021 USD 1,482.4 Million
Projected Market Size in 2028 USD 2,067.36 Million
CAGR Growth Rate 5.70% CAGR
Base Year 2021
Forecast Years 2022-2028
Key Market Players AbbVie Inc., Aurobindo Pharma, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Lupin Pharmaceuticals Inc., Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd., Albemarle Corporation, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Pfizer Inc., Sanofi, AstraZeneca, Baxter, and Others
Key Segment By API Type, Drug, Customer Base, Application, and Region
Major Regions Covered North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Purchase Options Request customized purchase options to meet your research needs. Explore purchase options

Market Dynamics

Over the projection period, an increase in chronic diseases, including diabetes and cancer, is anticipated to fuel the expansion of the pharmaceutical sector. Additionally, a rise in the number of elderly people who are susceptible to serious diseases will spur market expansion throughout the course of the projection period. The market scope will grow during the anticipated time frame as a result of the significant funding allocated for research activities.

Reduced demand for prescription medicine, growing competition from generic pharmaceuticals, pharmaceutical fraud, etc., are some of the restraints in the pharmaceutical sector. Low returns on investment in the pharmaceuticals sector as a result of price controls, cost-containing programs, and mandated cost savings will further impede corporate growth over the projection period.

Browse the full “Pharmaceutical Market Size, Share, Growth Analysis Report – Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028” Report at https://www.fnfresearch.com/pharmaceutical-market

Pharmaceutical Market: COVID-19 Impact Analysis

Advertisement
Stake.com

Because of the disruption caused by COVID, the market around the world has been significantly affected, which has caused many challenges in the supply chain of many essential goods. The growth of the healthcare industry, on the other hand, has been of significant benefit to the pharmaceutical industry. The pharmaceutical industry is now dealing with the repercussions of the COVID-19 epidemic and adjusting to new conditions, so this remark is true for the industry as a whole. With challenges comes opportunity, and this adage is accurate for the pharmaceutical sector. In many companies, the increased investment in high-tech and research and development has led to an increase in the effectiveness of teams.

The manufacturing process is one area that life science companies all across the world are working to enhance with the use of cloud computing, machine learning, artificial intelligence, and other digital initiatives. Benefits include determining which medications are the most effective for treating a patient’s condition; conducting drug design trials on a limited budget; determining when to begin and end medical treatment; efficiently collecting data pertaining to the patient’s health; and many other advantages.

Segmentation AnalysisAnalysis

The pharmaceutical market is segregated based on API type analysis, drug type analysis, customer base type analysis, and application analysis.

Based on API type analysis, the market is divided into synthetic API, biotech API, monoclonal antibodies, cytokines, vaccines, blood factors, hormones & growth factors, fusion proteins, and therapeutic enzymes. In 2021, synthetic API had a significant share. Based on drug type analysis, the market is divided into prescription drugs and OTC drugs. In 2021, prescription drugs dominated the global market. Based on customer base type analysis, the market is divided into generic drugs and branded drugs. In 2021, branded drugs had a major share.

Advertisement
Stake.com

Based on application analysis, the market is divided into oncology, ophthalmology, cardiovascular disease, gastrointestinal disorders, diabetes, endocrinology, central nervous system & neurological disorders, nephrology, and others. In 2021, the oncology category had a major share in the global market.

Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/pharmaceutical-market

Competitive Landscape

Some of the main competitors dominating the global Pharmaceutical market include – 

  • AbbVie Inc.
  • AurobindoPharma
  • BoehringerIngelheim International GmbH
  • Eli Lilly and Company
  • Lupin Pharmaceuticals Inc.
  • Abbott Laboratories
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Albemarle Corporation
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Sanofi
  • AstraZeneca
  • Baxter

Key Insights from Primary Research:

  • As per the analysis shared by our research analyst, the Pharmaceutical market is estimated to grow annually at a CAGR of around 5.70% over the forecast period (2022-2028).
  • In Terms Of Revenue, The Pharmaceutical market size was valued at around USD 1,482.4 million in 2021 and is projected to reach USD 2,067.36 million by 2028. Due to a variety of driving factors, the market is predicted to rise at a significant rate.
  • By Drug Type Analysis, Drugs dominated the market in 2021
  • By Application analysis, medications for metabolic diseases dominated the sector in 2021
  • In 2021, North America led the market. This is due to many strategic pharmaceutical alliances, particularly among the region’s well-established and early-stage businesses.

Have Any Query? Ask Our Experts: https://www.fnfresearch.com/inquiry/pharmaceutical-market

Key questions answered in this report:

Advertisement
Stake.com
  • What is the market size and growth rate forecast for Pharmaceutical industry?
  • What are the main driving factors propelling the Pharmaceutical Market forward?
  • What are the leading companies in the Pharmaceutical Industry?
  • What segments does the Pharmaceutical Market cover?
  • How can I receive a free copy of the Pharmaceutical Market sample report and company profiles?

Key Offerings:

  • Market Size & Forecast by Revenue | 2022−2028
  • Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities
  • Market Segmentation – A detailed analysis by API Type, Drug, Customer Base, Application, and Region
  • Competitive Landscape – Top Key Vendors and Other Prominent Vendors

Regional Dominance:

With the largest market share, North America dominated in the year 2021. This is due to a significant number of strategic pharmaceutical alliances, particularly among the region’s well-established and early-stage businesses. Additionally, the United States held the top spot in the world for expenditure on prescription drugs per person. Additionally, the majority of clinical trials and drug efficacy studies conducted worldwide were in the United States.

Due to its sizable consumer base, rising healthcare costs, increasing disease incidence, and the existence of supportive regulatory frameworks, Asia Pacific is anticipated to see the highest growth of any regional market throughout the forecast period. Big data and Artificial Intelligence (AI) application in Asian nations has been encouraged by a number of national-level regulations.

Recent Developments

  • As businesses abandon the one-size-fits-all paradigm for treating common medical ailments, more people are adopting precision medicines. Major corporations are investing in the creation of tailored medications, including GSK, Teva Pharmaceuticals, and AstraZeneca.

Request for Customization on this Report as per your requirements – https://www.fnfresearch.com/customization/pharmaceutical-market

(We tailor your report to meet your specific research requirements. Inquire with our sales team about customising your report.)

The global pharmaceutical market is segmented as follows:                                 

Advertisement
Stake.com

By API Type Analysis

  • Synthetic API
  • Biotech API
  • Monoclonal Antibodies
  • Cytokines
  • Vaccines
  • Blood Factors
  • Hormones & Growth Factors
  • Fusion Proteins
  • Therapeutic Enzymes

By Drug Type Analysis

  • Prescription Drugs
  • OTC Drugs

By Customer Base Type Analysis

  • Generic Drugs
  • Branded Drugs

By Application Analysis

  • Oncology
  • Ophthalmology
  • Cardiovascular Disease
  • Gastrointestinal Disorders
  • Diabetes
  • Endocrinology
  • Central Nervous System & Neurological Disorders
  • Nephrology
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • France
    • UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific
  • The Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

To know an additional revised 2022 list of market players, request a sample report: https://www.fnfresearch.com/sample/pharmaceutical-market

Browse Other Related Research Reports from Facts & Factors:

• Global Dietary Fiber Market Share Is Likely To Reach At A CAGR Value Of Around 10.80% By 2028: https://www.fnfresearch.com/dietary-fiber-market

• Global 3D Printing in Healthcare Market Share Is Expected to Grow At A CAGR Value Of Around 19.02% By 2028: https://www.fnfresearch.com/3d-printing-in-healthcare-market

• Global Goat Milk Powder Market Share Is Expected to Grow At A CAGR Value Of Around 8.2% By 2028: https://www.fnfresearch.com/goat-milk-powder-market

Advertisement
Stake.com

• Global Oxygen Market Size & Share Value Projected Over USD 83 Billion by 2028: https://www.fnfresearch.com/oxygen-market

• Global Nitrogen Market Size is Expected to Reach Around USD 21.7 Billion by 2028: https://www.fnfresearch.com/nitrogen-market

• Global Menstrual Cups Market Share to be worth around USD 980.4 Million by End of 2026: https://www.fnfresearch.com/menstrual-cups-market

About Facts & Factors:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Advertisement
Stake.com

Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Follow Us on LinkedIn: https://www.linkedin.com/company/fnfresearch

Follow Us on Twitter: https://twitter.com/fnfresearch

Follow Us on Facebook: https://www.facebook.com/factsandfactors/

Contact Us:

Advertisement
Stake.com

Rushikesh Dorge

USA: +1 347 690-0211

United Kingdom: +44 2032 894158

Japan: +81 50 5806 9039

India: +91 73877 19999

Advertisement
Stake.com

Email: [email protected]

Web: https://www.fnfresearch.com

Blog: https://www.fnfresearch.com/blog/

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

DCI Indonesia Awarded by Frost & Sullivan for World-class Operational Excellence, Enabling Customers to Grow and Thrive, and Securing a Market-leading Position

Published

on

dci-indonesia-awarded-by-frost-&-sullivan-for-world-class-operational-excellence,-enabling-customers-to-grow-and-thrive,-and-securing-a-market-leading-position

DCI Indonesia’s expansions, backed by its focus on industry best practices, sustainability, and alignment with customer trends, reinforce its strategic advantage.
SAN ANTONIO, July 3, 2024 /PRNewswire/ — Frost & Sullivan recently analyzed the data center services industry and, based on its findings, recognized DCI Indonesia with the 2024 Company of the Year Award for a fifth consecutive time. The company is the leading data center services provider in Indonesia, offering best-in-class, scalable, and reliable data center colocation services and solutions. Its portfolio includes colocation, bare metal, physical security, data center connectivity, cooling, and power management to improve operational excellence, enabling customers to grow and thrive. The company supports a diverse client base, including global cloud service providers, major e-commerce and social media companies, telecommunication service providers, financial services industries, and enterprises from various verticals.

DCI currently offers 83 megawatts (MW) of power capacity across Cibitung, Karawang and Jakarta, where clients can directly connect with 4 of the world’s biggest cloud platforms. The DCI Indonesia Platform maximizes headcount efficiency in data center operations and provides customers with improved power usage effectiveness and energy cost stability. Furthermore, DCI offers Renewable Energy Certificates (RECs), as well as green energy from biomass and solar farms as they lead the sustainability front in the industry.
Nishchal Khorana, global vice president and program leader for ICT at Frost & Sullivan, observed, “DCI Indonesia reinforces its strategic advantage with a compelling value proposition of tailored solutions and carrier-neutral facilities–the highest Tier IV service quality, best practice AI-driven operations, and competitive pricing. The company is an established data center operator with a 100% power uptime track record for over a decade, trusted by hundreds of clients in its portfolio to house their most critical IT infrastructure.”
DCI Indonesia is a member of a global business community that meets high social and environmental impact standards. With its sterling reputation and a client-centric approach at its core, it establishes ongoing trust with customers and fosters long-lasting relationships that extend throughout the data center service lifecycle. The company generates over USD $90 million in revenue, achieving at least 25% year-on-year growth with an impressive net profit margin. Its stellar growth momentum and trajectory are a testament to its service leadership, its ability to earn client trust and loyalty, and its capability to capture market share. The company is well-positioned to drive the data center service space into its next growth phase, capturing market share and sustaining its strategic leadership in the coming years.
“DCI Indonesia pioneers the highest standards, enabling its scalable, reliable, and carrier-neutral capabilities and services to meet clients’ ever-evolving digital infrastructure needs. Backed by its focus on operational excellence and sustainability, the company continues to expand in Indonesia,” added Riana Barnard, Best Practices Research Analyst.
Each year, Frost & Sullivan presents a Company of the Year Award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare industry participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the sector.
About Frost & SullivanFor six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:Tarini SinghP: +91-9953764546E: [email protected]
About DCI Indonesia PT DCI Indonesia Tbk (DCI) is the first Tier IV data center in Southeast Asia that provides secure data center infrastructure services, guaranteeing a 99.999% SLA colocation or only five minutes of downtime per year. As a neutral data center operator, DCI is supported by 70+ network service providers. DCI Platform has 7 data centers in 3 locations: Cibitung, Karawang, and Jakarta with a total potential power capacity approaching 1,000 megawatts (MW).
With world-class operating standards, and equipped with state-of-the-art data center equipment, DCI provides maximum availability for customers to access their critical assets. This includes financial institutions, network service providers, e-commerce players, cloud service providers, and companies from other sectors. DCI has maintained a 100% uptime track record since its establishment. This performance stems from the proven experience of the leadership team in information technology, data center services, and infrastructure management, spanning over 25 years.
The demand for data centers in Indonesia continues to grow rapidly. DCI responds to this by committing to build sustainable data centers across its existing and new locations.
Contact:DCI MarketingE: [email protected]
Photo – https://mma.prnewswire.com/media/2453096/DCl_Indonesia_Award.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dci-indonesia-awarded-by-frost–sullivan-for-world-class-operational-excellence-enabling-customers-to-grow-and-thrive-and-securing-a-market-leading-position-302188402.html

Continue Reading

Artificial Intelligence

Grant Cardone Lists $42M Miami Mansion on Blockchain Real Estate Platform Propy

Published

on

grant-cardone-lists-$42m-miami-mansion-on-blockchain-real-estate-platform-propy

American best-selling author, businessman, and investor chooses Propy’s onchain real estate platform to list Golden Beach, Florida, house.
MIAMI, July 2, 2024 /PRNewswire/ — Propy, a technology company revolutionizing real estate via blockchain and AI, today announced that high-profile American entrepreneur Grant Cardone has listed a Golden Beach, Florida, private property for sale on Propy’s blockchain-based real estate platform with an asking price of $42,000,000 accepting cryptocurrency. This marks the first venture into emerging technologies in proptech for Cardone, a serial founder, best-selling author, equity fund manager, and business and real estate investor. The home is listed on the Propy marketplace with the deed minted onchain.

Propy simplifies the home-purchasing experience and eliminates fraudulent transactions by using a decentralized title registry and an escrow settlement protocol for securely storing land records and facilitating transactions, as well as accepting or converting cryptocurrency if a buyer chooses this form of payment. Leveraging the immutability of the blockchain, Propy ensures that buyer and seller private information is secure throughout the transaction. Automating and bringing the entire process online and onchain enables closing on a property to be faster, easier, and more secure than the outdated, traditional real estate transaction model.
Commenting on the listing, Grant Cardone said, “We are all in on blockchain revolutionizing real estate. We are leveraging top-tier technology to make transactions seamless and unstoppable. This is the future of real estate, and we’re leading the charge!” 
The private address is minted on PropyKeys protocol – an onchain tokenized address market developed on the Base network (Coinbase Layer 2 on Ethereum). PropyKeys brings real estate onchain through NFT home addresses and aims to bring one million home addresses onchain by 2025. The Propy marketplace also grants prospective buyers the option to pay using Bitcoin or US dollars.
Natalia Karayaneva, Founder and CEO of Propy, said, “It is a privilege for us to be the platform of choice for high-end property sellers, enhancing our offering to our community of high net-worth individuals, investors, and crypto buyers. With Propy’s advanced blockchain rails, compliant crypto and dollar payments, and unwavering focus on privacy, our clients can confidently navigate the closing process. The inclusion of Cardone’s listing in BTC and USD on Propy, minted with our latest privacy deed feature, highlights our leadership in the intersection of real estate and crypto.”
Additional details on the Cardone property are available on Propy’s website. Interested parties should contact the listing agent for viewings and further details.
Natalia Karayaneva, Founder and CEO of Propy, is available for interview upon request.
About Propy:
Propy is a US-licensed title company and a pioneering platform leveraging blockchain and AI technology to facilitate seamless transactions of real-world assets (RWA), specifically focused on revolutionizing global real estate markets. As an industry leader, Propy specializes in providing secure and efficient solutions, ensuring an enhanced experience for buying and selling properties worldwide.
Website | Facebook | X 
Photo: https://mma.prnewswire.com/media/2452961/Grant_Cardone_mansion.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/grant-cardone-lists-42m-miami-mansion-on-blockchain-real-estate-platform-propy-302188274.html

Continue Reading

Artificial Intelligence

DataLend: Securities Lending Revenue Down 16% Year-Over-Year to $2.53 Billion in Q2 2024

Published

on

datalend:-securities-lending-revenue-down-16%-year-over-year-to-$2.53-billion-in-q2-2024

Global revenue declines year-over-year due to lagging equities performance in the U.S. and EMEA
NEW YORK, July 2, 2024 /PRNewswire/ — The global securities finance industry generated $2.53 billion in revenue for lenders in the second quarter of 2024, according to DataLend, the market data service of fintech EquiLend. The figure represents a 16% decrease from the $3.00 billion generated in Q2 2023.

Global broker-to-broker activity, where broker-dealers lend and borrow securities from each other, generated an additional $696 million in revenue during Q2, a 9% decrease year-over-year.
Regionally, equity revenue fell 33% in EMEA and 19% in North America compared to the same period last year. A 22% decline in fees in North America and a 23% dip in EMEA accounted for the majority of the decreased revenue. Equity revenue in APAC increased 8% thanks to a 13% increase in fees.
Global fixed income performance declined by 11% in Q2 year-over-year. While revenue from government securities was roughly flat, corporate debt revenue fell by 32%, a regression of a trend which saw corporate bonds running hot through much of 2022 and 2023.
In June 2024, the global securities finance industry generated $790 million in revenue for lenders. The figure represents a 11% decrease year-over-year from the $888 million generated in June 2023. Broker-to-broker activity totaled an additional $207 million in revenue in June, also an 11% decrease year-over-year.
The top five earners in June 2024 were Lucid Group (LCID US), Trump Media & Technology Group (DJT US), Canopy Growth Corporation NPV (CGC US & WEED CN), Beyond Meat Inc. (BYND US) and ImmunityBio Inc. (IBRX US). In total, the group generated $56 million in revenue in the month.
Bloomberg Terminal users can subscribe to EquiLend’s exclusive Orbisa securities lending data by entering terminal shortcut APPS ORBISA or clicking the following link: https://blinks.bloomberg.com/screens/apps%20orbisa.
About DataLend 
DataLend, the market data service within EquiLend’s Data & Analytics Solutions group, tracks daily market movements across more than 200,000 securities, covering $35 trillion in lendable assets and $2.6 trillion in on-loan assets for the securities finance market. www.datalend.com
About EquiLend
EquiLend is a global financial technology firm offering Trading, Post-Trade, Data & Analytics, RegTech and Platform Solutions for the securities finance industry. With offices in North America, EMEA and Asia-Pacific, EquiLend operates across various jurisdictions worldwide, adhering to the highest regulatory standards. The company is committed to excellence and innovation and is consistently recognized for its contributions to the industry. EquiLend is Great Place to Work Certified™ in the U.S., UK, Ireland and India and has been honored as the Best Post-Trade Service Provider Globally, Best Market Data Provider Globally and for its outstanding Diversity & Inclusion initiatives in the Securities Finance Times Industry Excellence Awards 2023. www.equilend.com
Logo – https://mma.prnewswire.com/media/1060364/EquiLend_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/datalend-securities-lending-revenue-down-16-year-over-year-to-2-53-billion-in-q2-2024–302188137.html

Continue Reading

Trending